Cp Kelco U.s., Inc.

Bio-bedst Aps

Liplasome Pharma Aps

Sune Allan Petersen

Anders Falk Vikbjerg

Mogens Winkel Madsen

Fredrik Melander

Andrew John Ryder

JeRay Jay Rosas

Willis C Baldwin, Jr

Lan Ma

Jan Larsen

Justin Bradford Thompson

Bastian Borum Andersen

Jonas Rosager Henriksen

Kent Jørgensen

Morten Just Petersen

Kent Joergensen

Disclosed herein is a sphingan oligosaccharide composition, its uses, and a process for preparing the same.

Sphingan oligosaccharides

The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.

Medical use of sPLA2 hydrolysable liposomes

The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.

Liposomes for drug delivery and methods for preparation thereof

The present invention provides a composition comprising a sPLA2 hydrolysable liposome, an exterior solution, and an interior solution within the liposome, &#x2014;wherein the concentration of osmolytes is higher in the interior solution than in the exterior solution. The composition improves storage stability of sPLA2 hydrolysable liposomes, in particular at when stored at 2-8 degrees Celsius. The liposome preferably encapsulates cisplatin. The invention also provides methods of preparing the composition of the invention.

SPLA2 hydrolysable liposomes with improved storage stability

Growing community of inventors

Greve, Denmark

Sune Allan Petersen